多变量遗传学分析证实人白细胞抗原-C位点rs5010528对莫桑比克接受奈韦拉平治疗的HIV人群史蒂文斯-约翰逊综合征/中毒性表皮坏死松解症易感性的显著贡献
在莫桑比克接受奈韦拉平治疗的HIV人群中,rs5010528与SJS/TEN易感性显著相关,基因型水平OR=5.72(P=0.0002),等位基因水平OR=3.51(P=0.0002);多变量分析显示HLA-C SNP、CYP2B6(rs28399499)、TRAF3IP2(rs76228616)和GSTM1(null基因型)可解释25%的易感性,其中HLA-C SNP贡献最显著(P=0.02,OR=5.64)。
要点
- rs5010528变异等位基因在SJS/TEN病例中比对照组更常见,携带者发生该不良反应的风险高(基因型水平OR=5.72)。
- 多变量分析中HLA-C SNP是最显著贡献因素(P=0.02,OR=5.64),与其他遗传因素共解释25%易感性。
- 作者认为rs5010528可作为不同撒哈拉以南人群SJS/TEN易感性的良好基因组生物标志物。
核心结论
- 本研究证实HLA-C区域rs5010528 SNP与莫桑比克人群发生SJS/TEN的易感性相关,提示其可作为不同撒哈拉以南人群SJS/TEN易感性的良好基因组生物标志物。
研究设计与样本
- 病例对照关联研究,纳入27例奈韦拉平治疗后发生SJS/TEN的患者和75例未发生不良反应的患者,采用直接测序分析rs5010528 SNP,并进行多变量分析评估HLA-C与其他易感基因(CYP2B6、TRAF3IP2、HCP5、PSORS1C1和GSTM1)的关系。
主要发现
- rs5010528与发生SJS/TEN的较高风险显著相关,变异等位基因在病例中比对照组更频繁,携带者发生该不良反应的风险高(基因型水平OR=5.72,P=0.0002;等位基因水平OR=3.51,P=0.0002)。
- 多变量分析显示HLA-C SNP、CYP2B6(rs28399499)、TRAF3IP2(rs76228616)和GSTM1(null基因型)可解释25%的该反应易感性,其中HLA-C SNP贡献最显著(P=0.02,OR=5.64)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Nevirapine is used in developing countries for the treatment of HIV infection, but its use is associated with rare serious adverse reactions such as Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN). Recently, an association between rs5010528 in the human leucocyte antigen (HLA)-C locus and SJS/TEN susceptibility has been described in sub-Saharan populations. Our aim was to verify this association in a population of nevirapine-treated patients from Mozambique. METHODS: The rs5010528 SNP was analysed by direct sequencing in 27 patients who had developed SJS/TEN and 75 patients who did not develop adverse reactions after nevirapine treatment. A case-control association study was conducted. A multivariate analysis was performed in order to evaluate the role of HLA-C also in relation to other susceptibility genetic factors (CYP2B6, TRAF3IP2, HCP5, PSORS1C1 and GSTM1 genes). RESULTS: rs5010528 was significantly associated with a higher risk of developing SJS/TEN; the variant allele was more frequent in cases than in controls, conferring a high risk of developing this adverse reaction in carriers (OR = 5.72 and P = 0.0002 at genotype level, OR = 3.51 and P = 0.0002 at allelic level). The multivariate analysis showed that the HLA-C SNP, CYP2B6 (rs28399499), TRAF3IP2 (rs76228616) and GSTM1 (null genotype) can explain 25% of the susceptibility to this reaction, with the HLA-C SNP as the most significant contributor (P = 0.02 and OR = 5.64). CONCLUSIONS: Our study confirmed the association of the rs5010528 SNP in the HLA-C region with susceptibility to developing SJS/TEN in a population from Mozambique, suggesting that it could be a good genomic biomarker for SJS/TEN susceptibility in different sub-Saharan populations.
引用
- Ciccacci C, Politi C, Mancinelli S, et al. A multivariate genetic analysis confirms rs5010528 in the human leucocyte antigen-C locus as a significant contributor to Stevens-Johnson syndrome/toxic epidermal necrolysis susceptibility in a Mozambique HIV population treated with nevirapine. J Antimicrob Chemother. 2018. PMID: 29762688. doi:10.1093/jac/dky180
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。